Stifel Financial
DNA icon

Stifel Financial’s Ginkgo Bioworks DNA Stock Holding History

Stifel Financial’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,496
Closed -$33.4K – 3389
2024
Q2 		$33.4K Sell
2,496
-3,138
-56% -$93.6K ﹤0.01% 3303
2024
Q1 		$261K Buy
5,634
+1,660
+42% +$85.9K ﹤0.01% 2981
2023
Q4 		$269K Buy
3,974
+301
+8% +$18.4K ﹤0.01% 2905
2023
Q3 		$266K Buy
3,673
+724
+25% +$57.9K ﹤0.01% 2851
2023
Q2 		$219K Buy
2,949
+468
+19% +$27.7K ﹤0.01% 2993
2023
Q1 		$132K Buy
2,481
+409
+20% +$25.9K ﹤0.01% 3133
2022
Q4 		$140K Buy
2,072
+359
+21% +$33K ﹤0.01% 3074
2022
Q3 		$214K Buy
1,713
+218
+15% +$26K ﹤0.01% 2906
2022
Q2 		$142K Buy
1,495
+489
+49% +$59.6K ﹤0.01% 3093
2022
Q1 		$162K Buy
+1,006
New +$196K ﹤0.01% 3183

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Stifel Financial's DNA Position: Q3 2024 in Review

Stifel Financial sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 2,496 shares — an estimated $33.4K sold.

Stifel Financial first reported a position in DNA in Q1 2022 and held it in 10 quarters. The position peaked at $269K in Q4 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Stifel Financial reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Stifel Financial sold 2,496 Ginkgo Bioworks shares in Q3 2024, an estimated $33.4K.
  • Stifel Financial first reported a position in Ginkgo Bioworks in Q1 2022 and held it in 10 quarters.
  • Stifel Financial's Ginkgo Bioworks position peaked at $269K in Q4 2023.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Stifel Financial's 13F filing for Q3 2024, filed 14 Nov 2024.